View in EDS HTML Full Text PDF Full Text

Favorable Rates of Cardiovascular Events with Stringent Cardiovascular Monitoring and a Lowered Dose of Ponatinib as Second-Line Treatment in Chronic Phase Chronic Myeloid Leukemia Patients Failing or Intolerant to First-Line Second-Generation Tyrosine Kinase Inhibitor Treatment: Results of the Prospective PONS Trial

Saved in:
Bibliographic Details
Title: Favorable Rates of Cardiovascular Events with Stringent Cardiovascular Monitoring and a Lowered Dose of Ponatinib as Second-Line Treatment in Chronic Phase Chronic Myeloid Leukemia Patients Failing or Intolerant to First-Line Second-Generation Tyrosine Kinase Inhibitor Treatment: Results of the Prospective PONS Trial
Authors: le Coutre, Philipp1 (AUTHOR), Burchert, Andreas2 (AUTHOR), Saußele, Susanne3 (AUTHOR), Schwarzer, Thekla1 (AUTHOR), Stintzing, Sebastian1 (AUTHOR), Pelzer, Uwe1 (AUTHOR), Bullinger, Lars1 (AUTHOR), Elmaagacli, Ahmet4 (AUTHOR), Jehn, Christian1,3 (AUTHOR), Stegelmann, Frank5 (AUTHOR), Hochhaus, Andreas6 (AUTHOR), Ernst, Thomas6 (AUTHOR), Göthert, Joachim R.7 (AUTHOR)
Source: Acta Haematologica. 2026, Vol. 149 Issue 3, p355-362. 8p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:00015792
DOI:10.1159/000545826